Comparative Effect of Basti therapy of Ayurveda in chronic kidney disease treatment

Not Applicable

• Conditions: Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)

• Registration Number: CTRI/2024/07/070318
• Lead Sponsor: All India Institute of Ayurveda (AIIA)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Patients of both genders having age group 21-65 yrs. with

confirmed diagnosis of stage up to G3-B as per standard

KDIGO-CRITERIA, not having undergone RRT were included.

2. Patients under controlled Diabetes and Hypertension with or

without conventional medications.

Exclusion Criteria

1. Patients suffering from Tuberculosis, Malignancy, Pregnancy and

lactation, or any other systemic illness.

2. Uncontrolled diabetes and HTN

3. HIV-associated nephropathy and transplant allograph failure

4. Renal Artery stenosis.

5. Neoplasm of Kidney.

6. History of previous kidney transplant.

7. Patients of Congenital Renal Diseases like Autosomal dominant

and Recessive Polycystic Kidney disease, Congenital Nephrotic

syndrome, Alports syndrome, Fabrys disease and juvenile

Nephronophthisis.

8. Patients with other added complications

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction in the values of KFT (Sr Creatinine, Blood urea, Serum Uric acid level) and <br/ ><br>to improve estimated Glomerular Filtration Rate (e-GFR)Timepoint: KFT assessed at Baseline, 15th, 30th 45th and 60th (AT), after 2-month FU. <br/ ><br>e-GFR assessed at BT, AT, after 2-month FU.

Secondary Outcome Measures

Name	Time	Method
1. To improve Hb%. <br/ ><br>2. To reduce Albuminuria. <br/ ><br>3. To improvement in signs and symptoms of CKD <br/ ><br>4. Assessment of quality of life by-Kidney Disease Quality of Life Short Form <br/ ><br>(KDQOL-SF™) <br/ ><br>5. To analyze electrolyte imbalance.Timepoint: 1. Hemoglobin assessed at BT, 15th, AT, after 2-month FU <br/ ><br>2. Albuminuria assessed at BT, 15th, after AT, 2-month FU. <br/ ><br>3. Signs and symptoms of CKD at BT, AT, after 2-monthsFU <br/ ><br>4. Quality of life of patients at BT, AT, after 2-months FU <br/ ><br>5. Sr Electrolyte assessed at BT, 15th, AT, after 2-month FU.